Discounted Cash Flow
Aurinia Pharmaceuticals Inc.
—
—
⚠ Cash flow predictability 42/100 (moderate) —
FCF YoY std dev 72%,
net income 72% (full history)
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $213.1k | $-30.8m | $-23.0m | -14466.5% | $-0.66 |
| 2017 | $517.3k (142.8%) | $-57.7m (-87.3%) | $-50.7m (-120.0%) | -11159.0% (22.9%) | $-0.92 (-39.4%) |
| 2018 | $570.2k (10.2%) | $-78.9m (-36.7%) | $-63.6m (-25.4%) | -13833.0% (-24.0%) | $-0.76 (17.4%) |
| 2019 | $391.6k (-31.3%) | $-152.4m (-93.1%) | $-78.2m (-23.0%) | -38900.0% (-181.2%) | $-1.33 (-75.0%) |
| 2020 | $61.7m (15660.4%) | $-126.5m (17.0%) | $-86.0m (-10.1%) | -204.9% (99.5%) | — |
| 2021 | $56.2m (-9.0%) | $-222.9m (-76.2%) | $-194.2m (-125.7%) | -396.8% (-93.7%) | $-1.40 |
| 2022 | $165.1m (193.9%) | $-133.2m (40.2%) | $-98.3m (49.4%) | -80.7% (79.7%) | $-0.76 (45.7%) |
| 2023 | $216.2m (31.0%) | $-96.1m (27.9%) | $-42.1m (57.2%) | -44.5% (44.9%) | $-0.54 (28.9%) |
| 2024 | $289.6m (34.0%) | $7.1m (107.4%) | $54.3m (229.0%) | 2.4% (105.5%) | $0.04 (107.4%) |
| 2025 | $348.6m (20.4%) | $353.7m (4893.1%) | $166.8m (207.0%) | 101.5% (4047.7%) | $2.14 (5250.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in CHF. Values above are converted to USD for comparison with the US-listed share price.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Net debt deduction: —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.